1. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography
- Author
-
Pitak Santanirand, Nitima Suttipanta, Siriluk Rattanabunyong, Poonpilas Hongmanee, Patchreenart Saparpakorn, Pornpan Pungpo, Thimpika Pornprom, Adrian J. Mulholland, Supaporn Seetaha, Khomson Suttisintong, Potjanee Srimanote, Kampanart Chayajarus, Rosemary A. Blood, Naruedon Phusi, Zhaoqiang Chen, Sanya Sureram, Pharit Kamsri, Supa Hannongbua, Philip Hinchliffe, Prasat Kittakoop, Kiattawee Choowongkomon, James Spencer, Yuiko Takebayashi, Chomphunuch Songsiriritthigul, Chayanin Hanwarinroj, Weiliang Zhu, and Auradee Punkvang
- Subjects
Stereochemistry ,General Chemical Engineering ,Antitubercular Agents ,Microbial Sensitivity Tests ,Library and Information Sciences ,Crystallography, X-Ray ,01 natural sciences ,Molecular Docking Simulation ,Mycobacterium tuberculosis ,Structure-Activity Relationship ,Bacterial Proteins ,Drug Discovery ,0103 physical sciences ,Structure–activity relationship ,Binding site ,Virtual screening ,Binding Sites ,Molecular Structure ,010304 chemical physics ,biology ,Drug discovery ,Chemistry ,INHA ,Reproducibility of Results ,General Chemistry ,biology.organism_classification ,0104 chemical sciences ,Computer Science Applications ,010404 medicinal & biomolecular chemistry ,Docking (molecular) ,Oxidoreductases - Abstract
The enoyl-acyl carrier protein reductase InhA of Mycobacterium tuberculosis is an attractive, validated target for antituberculosis drug development. Moreover, direct inhibitors of InhA remain effective against InhA variants with mutations associated with isoniazid resistance, offering the potential for activity against MDR isolates. Here, structure-based virtual screening supported by biological assays was applied to identify novel InhA inhibitors as potential antituberculosis agents. High-speed Glide SP docking was initially performed against two conformations of InhA differing in the orientation of the active site Tyr158. The resulting hits were filtered for drug-likeness based on Lipinski’s rule and avoidance of PAINS-like properties and finally subjected to Glide XP docking to improve accuracy. Sixteen compounds were identified and selected for in vitro biological assays, of which two (compounds 1 and 7) showed MIC of 12.5 and 25 μg/mL against M. tuberculosis H37Rv, respectively. Inhibition assays against purified recombinant InhA determined IC50 values for these compounds of 0.38 and 0.22 μM, respectively. A crystal structure of the most potent compound, compound 7, bound to InhA revealed the inhibitor to occupy a hydrophobic pocket implicated in binding the aliphatic portions of InhA substrates but distant from the NADH cofactor, i.e., in a site distinct from those occupied by the great majority of known InhA inhibitors. This compound provides an attractive starting template for ligand optimization aimed at discovery of new and effective compounds against M. tuberculosis that act by targeting InhA.
- Published
- 2019
- Full Text
- View/download PDF